Evidence map›Paper›PMID 24146990›Full record

ArticlePloS one2013

Large extracellular loop of tetraspanin as a potential vaccine candidate for filariasis.

Gajalakshmi Dakshinamoorthy, Gnanasekar Munirathinam, Kristen Stoicescu, Maryada Venkatarami Reddy, Ramaswamy Kalyanasundaram

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 34 citations in OpenAlex.

  1. Identification ofFrontiers in parasitology · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Molecular Characterization of a Tetraspanin TSP11 Gene inFrontiers in veterinary science · 2021
    Article
  8. Highlighting the Relevance of CD8Frontiers in immunology · 2021
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Gajalakshmi DakshinamoorthyDepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, Illinois, United States of America.
Gnanasekar Munirathinam
Kristen Stoicescu
Maryada Venkatarami Reddy
Ramaswamy Kalyanasundaram
Illinois College · USMahatma Gandhi Institute of Medical Sciences · INUniversity of Illinois Chicago, Rockford campus · US

Funding

MULTIVALENT VACCINE FOR LYMPHATIC FILARIASISR01AI064745 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KALYANASUNDARAM, RAMASWAMY · 2007 to 2010
$1.5M
NIAID NIH HHS R01 AI064745
6 · The paper itself

Abstract

Lymphatic filariasis affects nearly 120 million people worldwide and mass preventive chemotherapy is currently used as a strategy to control this infection. This has substantially reduced the incidence of the infection in several parts of the world. However, a prophylactic vaccine would be more effective in preventing future infections and will supplement the mass chemotherapy efforts. Unfortunately, there is no licensed vaccine available currently to prevent this infection. Molecules expressed on the surface of the parasite are potential candidates for vaccine development as they are exposed to the host immune system. In this study we show that the large extracellular loop of tetraspanin (TSP LEL), a protein expressed on the cuticle of Brugia malayi and Wuchereria bancrofti is a potential vaccine candidate. Our results showed that BmTSP LEL is expressed on the surface of B. malayi infective third stage larvae (L3) and sera from human subjects who are putatively immune to lymphatic filariasis carry high titer of IgG1 and IgG3 antibodies against BmTSP LEL and WbTSP LEL. We also showed that these antibodies in the sera of human subjects can participate in the killing of B. malayi L3 in an antibody dependent cell-mediated cytotoxicity mechanism. Vaccination trials in mice showed that close to 64% protection were achieved against challenge infections with B. malayi L3. Immunized animals showed high titer of anti-WbTSP LEL IgG1, IgG2a and IgG2b antibodies in the sera and IFN-γ secreting cells in the spleen. Onchocerca volvulus another filarial parasite also expresses TSP LEL. Cross-reactivity studies showed that IgG1 antibody in the sera of endemic normal subjects, recognize OvTSP LEL. Similarly, anti-OvTSP LEL antibodies in the sera of subjects who are immune to O. volvulus were also shown to cross-react with rWbTSP LEL and rBmTSP LEL. These findings thus suggested that rTSP LEL can be developed as a potential vaccine candidate against multiple filarial infections.

Indexed as

Amino Acid SequenceAnimalsAntibodies, HelminthAntibody-Dependent Cell CytotoxicityAntibody SpecificityAntigens, HelminthBrugia malayiCross ReactionsCytokinesFilariasisGene ExpressionHelminth ProteinsHumansImmunoglobulin GMaleMiceAntibodies, HelminthAntigens, HelminthCytokinesHelminth ProteinsImmunoglobulin GTetraspaninsVaccines

Identifiers

PMID24146990
PMCPMC3795629
OpenAlexW2050615887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.